Alyea Therapeutics, a biotech firm focused on non-opioid pain treatments, will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026. CEO Amol Soin will hold investor meetings and present the company's pipeline, including low-dose naltrexone for Complex Regional Pain Syndrome and a topical pain-relief patch. This event offers Alyea a platform to attract investment and highlight its strategy to develop clinically meaningful therapies addressing unmet needs in chronic pain management.
Alyea Therapeutics is attending the ArcStone-Kingswood Growth Summit 2026 in Toronto. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 03:21 WIB: out of 91 priced US health stocks, 75 rose and 16 fell. Notable movers include AMWL at USD 13.76 (+5.85%), TDOC at USD 6.51 (+5.76%), and INO at USD 1.18 (-5.60%).
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
